Literature DB >> 34825343

Regenerative approaches to preserve pancreatic β-cell mass and function in diabetes pathogenesis.

Maria Fernanda Desentis-Desentis1.   

Abstract

In both type 1 diabetes (T1D) and type 2 diabetes (T2D), there is a substantial β-cell mass loss. Residual β-cell mass is susceptible to cellular damage because of specific pancreatic β-cell characteristics. β cells have a low proliferation rate, being in human adults almost zero and a low antioxidant system that makes β cells susceptible to oxidative stress and increases their vulnerability to cell destruction. Different strategies have been addressed to preserve pancreatic β-cell residual mass and function in patients with diabetes. However, the effect of many compounds proposed in rodent models to trigger β-cell replication has different results in human β cells. In this review, scientific evidence of β-cell of two major regenerative approaches has been gathered. Regeneration proceedings for pancreatic β cells are promising and could improve β-cell proliferation capacity and contribute to the conservation of mature β-cell phenotypic characteristics. This evidence supports the notion that regenerative medicine could be a helpful strategy to yield amelioration of T1D and T2D pathogenesis.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Dedifferentiation; Diabetes.; Proliferation; Redifferentiation; Regenerative; β-cell mass

Mesh:

Substances:

Year:  2021        PMID: 34825343     DOI: 10.1007/s12020-021-02941-5

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  49 in total

Review 1.  Development of the endocrine pancreas.

Authors:  David J Hill
Journal:  Rev Endocr Metab Disord       Date:  2005-08       Impact factor: 6.514

Review 2.  Programming of the endocrine pancreas by the early nutritional environment.

Authors:  Brigitte Reusens; Claude Remacle
Journal:  Int J Biochem Cell Biol       Date:  2005-11-10       Impact factor: 5.085

Review 3.  Molecular control of cell cycle progression in the pancreatic beta-cell.

Authors:  Irene Cozar-Castellano; Nathalie Fiaschi-Taesch; Todd A Bigatel; Karen K Takane; Adolfo Garcia-Ocaña; Rupangi Vasavada; Andrew F Stewart
Journal:  Endocr Rev       Date:  2006-04-25       Impact factor: 19.871

4.  Formation of a human β-cell population within pancreatic islets is set early in life.

Authors:  Brigid E Gregg; Patrick C Moore; Damien Demozay; Ben A Hall; Mei Li; Aliya Husain; Amy J Wright; Mark A Atkinson; Christopher J Rhodes
Journal:  J Clin Endocrinol Metab       Date:  2012-06-28       Impact factor: 5.958

Review 5.  Regulation of pancreatic beta-cell mass.

Authors:  Luc Bouwens; Ilse Rooman
Journal:  Physiol Rev       Date:  2005-10       Impact factor: 37.312

Review 6.  Pancreas regeneration.

Authors:  Qiao Zhou; Douglas A Melton
Journal:  Nature       Date:  2018-05-16       Impact factor: 49.962

Review 7.  The regulation of pre- and post-maturational plasticity of mammalian islet cell mass.

Authors:  Teresa Mezza; Rohit N Kulkarni
Journal:  Diabetologia       Date:  2014-05-14       Impact factor: 10.122

8.  Human β-cell proliferation and intracellular signaling: driving in the dark without a road map.

Authors:  Rohit N Kulkarni; Ernesto-Bernal Mizrachi; Adolfo Garcia Ocana; Andrew F Stewart
Journal:  Diabetes       Date:  2012-06-29       Impact factor: 9.461

9.  Survey of the human pancreatic beta-cell G1/S proteome reveals a potential therapeutic role for cdk-6 and cyclin D1 in enhancing human beta-cell replication and function in vivo.

Authors:  Nathalie Fiaschi-Taesch; Todd A Bigatel; Brian Sicari; Karen K Takane; Fatima Salim; Silvia Velazquez-Garcia; George Harb; Karen Selk; Irene Cozar-Castellano; Andrew F Stewart
Journal:  Diabetes       Date:  2009-01-09       Impact factor: 9.461

Review 10.  Pancreatic β Cell Mass Death.

Authors:  Husnia I Marrif; Salma I Al-Sunousi
Journal:  Front Pharmacol       Date:  2016-04-06       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.